Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 317.1% in April

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 105,100 shares, an increase of 317.1% from the March 31st total of 25,200 shares. Based on an average daily trading volume, of 497,100 shares, the days-to-cover ratio is presently 0.2 days. Approximately 25.0% of the company’s shares are short sold.

Allarity Therapeutics Stock Performance

ALLR stock opened at $1.43 on Friday. The company’s fifty day simple moving average is $5.71 and its 200 day simple moving average is $8.88. Allarity Therapeutics has a 12-month low of $1.27 and a 12-month high of $415.92.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Allarity Therapeutics stock. Sabby Management LLC bought a new position in Allarity Therapeutics, Inc. (NASDAQ:ALLR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 359,400 shares of the company’s stock, valued at approximately $268,000. Allarity Therapeutics makes up approximately 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 21st biggest position. Sabby Management LLC owned about 13.16% of Allarity Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 11.53% of the company’s stock.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.